The partnership aims to merge Dianosic’s clinical designs with Aptar Pharma’s proficiency in nasal drug delivery. Credit: Mariana Serdynska / Shutterstock.com.

Aptar Pharma and Dianosic have entered an exclusive partnership to develop an active resorbable intranasal scaffold (ARIS) platform to treat chronic allergic rhinitis (CAR) and chronic rhinosinusitis (CRS).

Aptar Pharma is a provider of drug delivery systems and material science solutions while Dianosic is a French biotech firm that focuses on intranasal therapies.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

The bioresorbable intranasal insert delivers medication locally over extended periods, addressing the unmet needs in these conditions.

The partnership will also investigate nose-to-brain (N2B) delivery methods, specifically for neuropsychiatric and neurodegenerative disorders.

It also seeks to improve patient adherence to treatment, thereby enhancing overall quality of life, according to Aptar Pharma.

Aptar Pharma prescription president Alex Theodorakis said: 鈥淭his partnership with Dianosic expands our commitment to deliver innovative and patient-centric solutions by leveraging the potential of intranasal drug-delivery.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

鈥淭his transformative innovation represents a promising advancement in the management of chronic rhinitis and sinusitis, and we are proud to support the ARIS journey to market.鈥�

The agreement includes Aptar Pharma’s investment in Dianosic and participation in its strategic committee, while also promoting the technology to its customer base.

This partnership integrates Dianosic鈥檚 clinical designs with Aptar Pharma鈥檚 expertise in nasal drug delivery, creating opportunities to explore the potential of N2B applications.

Dianosic CEO and co-founder Philippe Bastide said: 鈥淲e are thrilled to join forces with Aptar Pharma as it marks a major step towards making our drug-eluting resorbable Intranasal Scaffold platform accessible worldwide.

鈥淭his alliance supports our commitment to improving intranasal therapeutic options for patients with chronic nasal conditions.鈥�

In October 2024, Aptar Pharma acquired all device technology assets from SipNose Nasal Delivery Systems.

吃瓜黑料网 Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The 吃瓜黑料网 Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don鈥檛 miss your chance to stand out鈥攕ubmit your entry today!

Nominate Now